The interplay between cell signalling and the mevalonate pathway in cancer.
about
Cell membrane modulation as adjuvant in cancer therapyDietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancerOpposite feedback from mTORC1 to H-ras and K-ras4B downstream of SREBP1.Lung tumors with distinct p53 mutations respond similarly to p53 targeted therapy but exhibit genotype-specific statin sensitivityA transcriptome-based protein network that identifies new therapeutic targets in colorectal cancer.Deregulated expression and activity of Farnesyl Diphosphate Synthase (FDPS) in Glioblastoma.Mevalonate metabolism governs cancer immune surveillance.Identification and characterization of genes involving the early step of Juvenile Hormone pathway in Helicoverpa armigera.Lovastatin induced Kruppel like factor 2 (KLF2), Kruppel like factor 6 (KLF6) and Ras homolog family member B (RHOB) genes and preferentially led to viability reduction of Cisplatin-resistant cells.Atorvastatin downregulates co-inhibitory receptor expression by targeting Ras-activated mTOR signalling.Aminoacylase 3 Is a New Potential Marker and Therapeutic Target in Hepatocellular Carcinoma.Atorvastatin exhibits anti-tumorigenic and anti-metastatic effects in ovarian cancer in vitro.Cell size control - a mechanism for maintaining fitness and function.Mechanical cues control mutant p53 stability through a mevalonate-RhoA axis.The interplay between mutant p53 and the mevalonate pathway.Simvastatin Inhibits Cell Proliferation and Migration in Human Anaplastic Thyroid Cancer.Overexpression of geranylgeranyl diphosphate synthase contributes to tumour metastasis and correlates with poor prognosis of lung adenocarcinoma.On the structural intricacies of a metabolic precursor: Direct spectroscopic detection of water-induced conformational reshaping of mevalonolactone.Cilia loss sensitizes cells to transformation by activating the mevalonate pathway.Heteromeric interactions regulate butyrophilin (BTN) and BTN-like molecules governing γδ T cell biology.NK Cells and γδT Cells for Relapse Protection After Allogeneic Hematopoietic Cell Transplantation (HCT).Frequent overexpression of AMAP1, an Arf6 effector in cell invasion, is characteristic of the MMTV-PyMT rather than the MMTV-Neu human breast cancer model.Mitochondrial Acetyl-CoA Synthetase 3 is Biosignature of Gastric Cancer Progression.Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer.Mevalonate pathwayRelationship of SNP rs2645429 in Farnesyl-Diphosphate Farnesyltransferase 1 Gene Promoter with Susceptibility to Lung Cancer.Amino Acid Signature in Human Melanoma Cell Lines from Different Disease Stages.Altered membrane rigidity via enhanced endogenous cholesterol synthesis drives cancer cell resistance to destruxins.Targeting the mevalonate pathway is a novel therapeutic approach to inhibit oncogenic FoxM1 transcription factor in human hepatocellular carcinoma.Mevalonate Metabolism in Cancer Stemness and Trained ImmunityThe role of YAP/TAZ activity in cancer metabolic reprogramming
P2860
Q28078167-538726B6-99A3-41D0-87E3-230CE0098F83Q33906118-4C09DA60-F8D3-41A0-B8AC-ACB0089B7191Q38615220-2A11231C-0C8A-441D-82F8-3310FF44E56FQ38633269-D8B75A4F-9284-417A-9911-BDE359313304Q41949320-C5737FAE-A1CE-462E-997B-403A51C779BAQ42621057-BB35A061-7B21-4CF0-B36F-049B8489200EQ46592108-0D992B30-F33C-4F3C-80EE-21735CF59A3DQ47102628-A24BEBD4-D363-4BFD-ADD9-6736F8DFE1B9Q47118680-FB91CD7D-48F2-48F2-BFA2-69BB36633481Q47125276-284162A1-D0E6-4A68-B06E-BFBBE031FEE4Q47148678-78AE4FF1-A12F-416B-9596-24446218CA5DQ47193411-882238E7-0765-408B-8751-0721CF740C4CQ47197525-2A13A6A7-50E6-4628-B2EC-D31457171BD5Q47236792-127342CE-144A-41D1-A58C-D85EC92CA716Q47296038-748F4A69-384B-4E2E-B402-5556AB3C5EADQ47298592-9AF82C91-7B31-4B42-88FC-BCE2128D1604Q47645395-08A97BEF-EC63-4FA4-B2F4-60F65E2E17BAQ47862954-CB38A397-6711-4D95-91B3-EF96391E8629Q48122685-35F12DE9-25E5-46B9-B41B-C28BA28D736FQ48232215-A8B5DA73-4EDE-4F70-A2C9-2674640A47B9Q49333274-4CA844AB-56F5-4A2E-A0B3-4F0A05ABDC50Q49413628-35FBEF76-795C-47B7-927D-6327AE386FA3Q52680121-D0233968-5445-4935-A07E-8FE71F55CEBAQ52688122-27F1395F-2E67-40FD-B922-A9C7A22ACBBDQ54990302-6AF3920E-6692-4744-B5F2-62EABD56FB36Q55085412-254DA8EF-14F5-4217-B547-24B85E337320Q55091781-2EB2DF1B-1F0D-41C6-981A-A0BA5CA46CBAQ55175737-081E514F-39F8-4DE3-9D3C-63AF51BA4BB0Q55195973-2B2A9FD1-325B-4DC7-A743-EB6CB1996536Q57300154-9714ACCD-2240-4086-B674-01ECC9630CF5Q58768991-8E7EBD16-FE45-4940-92CA-723C161987EF
P2860
The interplay between cell signalling and the mevalonate pathway in cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
The interplay between cell signalling and the mevalonate pathway in cancer.
@en
type
label
The interplay between cell signalling and the mevalonate pathway in cancer.
@en
prefLabel
The interplay between cell signalling and the mevalonate pathway in cancer.
@en
P2860
P50
P356
P1476
The interplay between cell signalling and the mevalonate pathway in cancer.
@en
P2093
Michael C Archer
Peter J Mullen
P2860
P2888
P304
P356
10.1038/NRC.2016.76
P407
P577
2016-08-26T00:00:00Z
P6179
1052932418